Infectious Disease Advisor news story
An ibalizumab-based treatment approach demonstrates sustained effectiveness in heavily treatment-experienced individuals with multidrug-resistant HIV-1, with long-term virologic and immunologic outcomes comparable to matched patients not receiving ibalizumab despite more advanced baseline disease, according to study results presented at CROI 2026.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
View all Infectious Disease Advisor reports from CROI 2026
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.